Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 7, 2012; 18(33): 4604-4609
Published online Sep 7, 2012. doi: 10.3748/wjg.v18.i33.4604
Published online Sep 7, 2012. doi: 10.3748/wjg.v18.i33.4604
Figure 1 Frequency distribution of model for end-stage liver disease scores of patients receiving entecavir who survived (A) or succumbed (B).
Death occurred in 95% of patients with MELD score > 28.63, 96% with score > 29.39 and 97% with score > 30.69; and in 5% with score < 22.85, 4% with score < 22.26, and 3% with score < 21.97. The mortality rate was > 95% in patients with MELD score > 30, and > 95% patients survived with MELD score < 22. MELD: Model for end-stage liver disease.
- Citation: Yan Y, Mai L, Zheng YB, Zhang SQ, Xu WX, Gao ZL, Ke WM. What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients? World J Gastroenterol 2012; 18(33): 4604-4609
- URL: https://www.wjgnet.com/1007-9327/full/v18/i33/4604.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i33.4604